查詢結果分析
相關文獻
- 幽門螺旋桿菌藥物治療的現況
- 幽門螺旋桿菌除菌治療新趨勢
- One-Week Proton Pump Inhibitor-Based Triple Therapy Eradicates Residual Helicobacter Pylori after Failed Dual Therapy
- Impact of Helicobacter Pylori Antimicrobial Resistance on the Outcome of 1-Week Lansoprazole-Based Triple Therapy
- 益生菌降低幽門螺旋桿菌之療效
- 根除幽門螺旋桿菌之病例用藥探討
- 幽門螺旋桿菌現今治療進展
- 幽門螺旋桿菌抗藥性之機轉及盛行率
- 幽門螺旋桿菌除菌治療之新進展
- 幽門螺旋桿菌根除失敗原因及對策
頁籤選單縮合
題 名 | 幽門螺旋桿菌藥物治療的現況=Current Treatment Regimens for Helicobacter Pylori Infection |
---|---|
作 者 | 康建文; 張秋敏; 林伯昌; | 書刊名 | 藥學雜誌 |
卷 期 | 28:2=111 2012.06[民101.06] |
頁 次 | 頁55-59 |
分類號 | 418.24 |
關鍵詞 | 幽門螺旋桿菌; 三合一療法; 抗藥性; 根除率; Fluoroquinolones; |
語 文 | 中文(Chinese) |
中文摘要 | 幽門螺旋桿菌 (Helicobacter pylori; H. pylori; Hp) 已證實是造成胃炎、胃及十二指腸潰瘍之原兇,更被列為胃的第一級致癌物 (WHO 1994)。以氫質子幫浦抑制劑 (proton pump inhibitor; PPI) 為基礎合併兩種抗生素的『三合一』根除療法已廣泛地被使用。然而仍有約15-20%的病人無法有效地治癒。近幾年失敗的比率正快速增加,服藥順從性及細菌本身的抗藥性是主要因素。本文希望透過實證醫學的角度,探討相對於傳統三合一療法 (amoxicillin+clarithromycin+PPI) 及使用 levofloxacin 的臨床效益比較。 |
英文摘要 | Helicobacter pylori (Hp) has been confirmed that could cause gastritis, stomach and duodenal ulcer, and is listed as the first class of stomach's carcinogen (WHO 1994). Proton pump inhibitor (PPI) is the basic element to which combines two kinds of antibiotics then become as the so called triple therapy. And this way for eradicating the pathogens now is used wildly. However there still are about 15-20% patients who have failed in treatment by this Gold Rule. In recently, the ratio of treatment failure increases fast. The patients' compliance and pathogens resistance are considered the major reasons to make this condition. Based on the EBM (Evidence-Based-Medicines), the purpose of this study is to discuss the clinical benefit compared with using of levofloxacin to that of the traditional triple therapy (amoxicillin+clarithromycin+PPI). |
本系統中英文摘要資訊取自各篇刊載內容。